Immunome Reports Third Quarter 2023 Financial Results
– Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors
– Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO
– Bob Lechleider, M.D., appointed as Chief Medical Officer
– Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors
– Cash runway expected to extend into Q1 2026*